Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications
Open accessThe DOI matches its Crossref record; 215 of the 225 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC), a prevalent malignant tumor of the digestive system, ranks as the third and second in global incidence and mortality, respectively, in 2020, with 1.93 million new cases (≈10% of all cancers). There are 940,000 deaths (≈9.4% of all cancers), and the incidence of CRC in younger patients (under 50 years of age) has become a new trend. The pathogenesis of CRC is primarily attributed to a series of genetic and epigenetic abnormalities within normal colonic epithelial cells, coupled with the reshaping of the tumor microenvironment in the surrounding stroma. This process leads to the transformation of colorectal adenomas into invasive adenocarcinomas. Although genetic changes are known to be the primary driving force in the occurrence and progression of CRC, recent research indicates that epigenetic regulation serves as a crucial molecular marker in cancer, playing a significant role in the pathological and physiological control of interactions between genetics and the environment. This review discusses the current global epidemiology of CRC, its risk factors, and preventive treatment strategies. The current study explores the latest advancements in the epigenetic regulation of CRC, including DNA methylation, histone modifications, and non-coding RNAs (ncRNAs). These developments hold potential as screening tools, prognostic biomarkers, and therapeutic targets for CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Moreover, alterations in histone acetylation and methylation can lead to changes in KRAS expression, and H3K9 and H3K27 methylation can repress EGFR transcription, thus leading to resistance against cetuximab [55].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [55]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Epigenetic alterations can affect the expression of genes involved in drug transport and several signaling pathways in CRC cells, such as cell proliferation, survival, apoptosis, and DNA repair [23,55].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
miR-429 mediates tumor growth and metastasis in colorectal cancer.
Han, Y., Zhao, Q., Zhou, J., & Shi, R. (2017) · Europe PMC (PubMed Central) · Cited by 37
RetractedSung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · cited 3×
“…cancer, with 1.07 million new cases ( ≈ 10.6% of all cancers) and approximately 520,000 deaths ( ≈ 9.3% of all cancers); among females, CRC ranks as the second most common cancer after breast cancer, with 870,000 new cases ( ≈ 9.4% of all cancers) and 420,000 deaths ( ≈ 9.5% of all cancers) [2].”
BackgroundInfluentialInitial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“Classic CRC biomarkers, such as mutations in KRAS and BRAF, methylation modifications of NDRG4, BMP3, and SEPT9, high expression of miR-92a and miR-144, and the presence of F. nucleatum , are utilized in liquid biopsies for early CRC screening [8–12].”
BackgroundBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 2×
“The accumulation of cancer-driving gene mutations, epigenetic alterations, and environmental interactions are primary factors promoting the development of sCRC [18].”
BackgroundLandscape of transcription in human cells
Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012) · Nature · doi:10.1038/nature11233 · Cited by 5,187 · cited 1×
“The remaining 98% are ncRNAs, which, until recently, were considered transcriptional “noise” [117,118].”
BackgroundCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Moreover, alterations in histone acetylation and methylation can lead to changes in KRAS expression, and H3K9 and H3K27 methylation can repress EGFR transcription, thus leading to resistance against cetuximab [55].”
Theodorakis, N., Feretzakis, G., Tzelves, L., Paxinou, E., Hitas, C., Vamvakou, G., Verykios, V. S., & Nikolaou, M. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090931 · Cited by 51
“ML algorithms can analyze epigenomic data to detect aberrant methylation patterns and predict which individuals might benefit from DNMT inhibitors [56].”
BackgroundKaviarasan, V., Das, A., Deka, D., Saha, B., Banerjee, A., Sharma, N. R., Duttaroy, A. K., & Pathak, S. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04790-w · Cited by 53
Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies
Imran, K., Iqbal, M. J., Ahmed, M. M., Khalid, A., Cortés, H., Reyes‐Hernández, O. D., Figueroa‐González, G., Leyva‐Gómez, G., Falzone, L., Libra, M., et al. (2025) · Medical Oncology · doi:10.1007/s12032-025-02905-z · Cited by 29
“Aberrant DNA methylation and miRNA dysregulation have been extensively studied in colorectal cancer [121, 122].”
Khan, A. H., Hasana, U., Nadeem, I. A., Khatri, S. P., Nawaz, S., Makhdoom, Q. U., Wazir, S., Patel, K., & Ghaly, M. (2025) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-025-00277-z · Cited by 28
“Targeting lncRNAs and microbiota metabolites holds promise for CRC diagnosis and treatment, including second-generation multi-target stool RNA and DNA tests [44] .”
Metadata
- Authors
- Cao, Q., Tian, Y., Deng, Z., Yang, F., & Chen, E.
- Affiliations
- Northwest University (CN)
- Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Northwest University, Xi’an 710069, China
- Corresponding author
- Chen, Erfei
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-03-15
- Volume
- 25
- Issue
- 6
- Pages
- 3358
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10969857
- OpenAlex
- W4392865173
- Cited by
- 60
- References
- 225
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 9
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Shaanxi Fundamental Science Research Project for Chemistry and Biology (22JHQ084)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, epigenetic regulation, DNA methylation, histone modifications, non-coding RNA, prognostic factors, cancer screening, tumor microenvironment, colorectal adenoma, cancer risk factors, cancer prevention, therapeutic target
- MeSH terms
- Humans, Prognosis, Colorectal Neoplasms, Biomarkers, DNA Methylation, Epigenesis, Genetic, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications. https://app.cochat.ai/papers/10.3390/ijms25063358
- The paper
- Cao, Q., Tian, Y., Deng, Z., Yang, F., & Chen, E. (2024). Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
